

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Franz Paul ARMBRUSTER et al. Conf.:  
Appl. No.: NEW Group: Unassigned  
Filed: March 3, 2004 Examiner: UNASSIGNED  
For: FUNCTIONAL VITAMIN D DERIVATIVES AND  
METHOD OF DETERMINING 25-HYDROXY- AND  
1A,25-DIHYDROXY VITAMIN D

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION WITH CONTINUATION-IN-PART OR  
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

March 3, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form, attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form is requested since any patents, publications, or other information which are listed on the PTO-1449 form but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No.  
09/720,338

U.S. Filing Date  
February 20, 2001

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Mark J. Nuell, #36,623

DRN/TBS/bsh  
0756-0124P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 02/12/2004)

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)	ATTY. DOCKET NO. 0756-0124P	APPLICATION NO. NEW
	APPLICANT Franz Paul ARMBRUSTER et al.	
	FILING DATE March 3, 2004	GROUP Unassigned

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
	WO	97/24127	A1	1997-07-10	PCT				
	EP	0 312 360	A2	1989-04-19	EPO				

**OTHER DOCUMENTS**

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	Kobayashi et al., J. Steroid Biochem. Molec. Biol., Vol. 62, No. 1, pp.79-87, XP002119849 (1997)
	T. Higashi et al., Analytica Chimica Acta, Vol. 365, No. 1-3, pp.151-158, XP002119850 (1998)
	Roy et al., Steroids, Vol. 60, No. 8, pp.530-533 (1995)
	Swamy et al., Protein Expression and Purification, Vol. 6, No. 2, pp.185-186 (1995)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	